Aurinia Pharmaceuticals Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Aurinia Pharmaceuticals Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q3 2024.
  • Aurinia Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was $14.4M.
  • Aurinia Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$22.6M, a 70.8% increase year-over-year.
  • Aurinia Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$78M, a 27.9% increase from 2022.
  • Aurinia Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$108M, a 40.2% increase from 2021.
  • Aurinia Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$181M, a 76.2% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$22.6M $14.4M +$27.8M Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$50.3M $722K +$12.2M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$62.6M -$10.7M +$15.5M +59% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 -$78M -$26.9M -$829K -3.18% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 -$77.2M -$13.4M -$4.46M -49.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$72.7M -$11.5M +$24M +67.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$96.8M -$26.2M +$11.4M +30.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 -$108M -$26M +$7.28M +21.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 -$115M -$8.99M +$41.3M +82.1% Jul 1, 2022 Sep 30, 2022 10-K 2024-02-15
Q2 2022 -$157M -$35.5M +$11.5M +24.5% Apr 1, 2022 Jun 30, 2022 10-K 2024-02-15
Q1 2022 -$168M -$37.6M +$12.7M +25.3% Jan 1, 2022 Mar 31, 2022 10-K 2024-02-15
Q4 2021 -$181M -$33.3M -$25.2M -313% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 -$156M -$50.3M -$8.13M -19.3% Jul 1, 2021 Sep 30, 2021 10-K 2023-02-28
Q2 2021 -$148M -$47M -$20.5M -77.1% Apr 1, 2021 Jun 30, 2021 10-K 2023-02-28
Q1 2021 -$127M -$50.4M -$24.4M -94.3% Jan 1, 2021 Mar 31, 2021 10-K 2023-02-28
Q4 2020 -$103M -$8.07M +$26.4M +76.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-28
Q3 2020 -$129M -$42.1M -$18.7M -79.6% Jul 1, 2020 Sep 30, 2020 10-K 2022-02-28
Q2 2020 -$110M -$26.5M -$10.2M -62.1% Apr 1, 2020 Jun 30, 2020 10-K 2022-02-28
Q1 2020 -$100M -$25.9M -$11.8M -84% Jan 1, 2020 Mar 31, 2020 10-K 2022-02-28
Q4 2019 -$88.4M -$34.5M Oct 1, 2019 Dec 31, 2019 10-K 2021-02-24
Q3 2019 -$23.5M Jul 1, 2019 Sep 30, 2019 10-K 2021-02-24
Q2 2019 -$16.4M Apr 1, 2019 Jun 30, 2019 10-K 2021-02-24
Q1 2019 -$14.1M Jan 1, 2019 Mar 31, 2019 10-K 2021-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.